Replies to post #395709 on NorthWest Biotherapeutics Inc (NWBO)

[anders2211]

DCVax-Direct also collects monocytes from the patient’s blood, but these are not fully matured into dendritic cells in the laboratory. Instead, they are injected directly into the tumor inside the body, and are designed to encounter the cancer biomarkers and mature into “educated” dendritic cells that “educate” and activate the rest of the immune system to fight cancer cells.

The biggest difference is the way they are administered to the patient and before that prepared, but their MOA is very similar.

https://immuno-oncologynews.com/dcvax/?cn-reloaded=1

[biosectinvestor]

Which also could potentially make it less processed and easier to provide a faster approval. It is the patient’s own processed blood product, and potentially less problematic in terms of potential for contamination.

So I am not sure it poses the same potential road blocks as DCVax-L. Hard to know, but I won’t count out possibilities of advancing it very quickly on the validation of DCVax-L.